Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021

Rhea-AI Summary

Oyster Point Pharma (Nasdaq: OYST) will present multiple scientific papers at the American Academy of Ophthalmology Annual Meeting 2021 from November 12-15 in New Orleans, LA. Key highlights include data on TYRVAYA^TM (varenicline solution) Nasal Spray, recently approved for dry eye disease treatment. Notable presentations will feature studies on OC-01 Nasal Spray from clinical trials ONSET-1 and ONSET-2, exploring age stratifications and clinical outcomes. Dry eye disease affects 38 million people in the U.S., highlighting the urgency of effective therapies.

PRINCETON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced multiple scientific presentations at the American Academy of Ophthalmology (AAO) Annual Meeting 2021 being held in New Orleans, LA November 12^th – 15^th, 2021.

“The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons whose mission is to empower lives by serving as an advocate for patients and the public, leading ophthalmic education, and advancing the profession of ophthalmology.” said Marian Macsai, MD Chief Medical Officer of Oyster Point Pharma. “We are pleased to share a number of data presentations from company-sponsored clinical trials at this year’s meeting highlighting the recently approved TYRVAYA^TM (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.”

Papers/Posters

Title: ONSET-2 Phase 3 Trial of OC-01 (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease
Presenter: Marjan Farid, MD
Location: Morial Convention Center, Room 255-257
Presentation Date/time: November 14 at 8:48am–8:55am CST

Title: OC-01 Nasal Spray Clinical Sign Outcomes in Dry Eye Disease by Baseline Stratification Factors - Combined ONSET-1 & -2
Presenter: John D Sheppard MD
Location: Morial Convention Center, Hall C (Poster Theater and Lounge)
Presentation Date/Time: November 14 at 3:45-4:45 pm CST

Title: OC-01 (varenicline solution) Nasal Spray Clinical Sign Outcomes in Dry Eye Disease by Age and Artificial Tear Use – A Subgroup Analysis
Presenter: Alice T. Epitropoulos, MD
Location: Virtual
Presentation Date/Time: On Demand

About Dry Eye Disease and the Role of Tear Film
Dry eye disease is a chronic condition that impacts an estimated 38 million people in the U.S. and is growing in prevalence.^1,2 It can cause persistent stinging, scratching, burning sensations, sensitivity to light, blurred vision, and eye fatigue. Dry eye disease is a multifactorial disease of the ocular surface characterized by disruption of the tear film. Human tear film is a complex mixture of more than 1,500 different proteins, including growth factors and antibodies, as well as numerous classes of lipids and mucins.³ Natural tear film protects and lubricates the eyes, washes away foreign particles, contains growth factors and antimicrobial components, and creates a smooth surface that forms the primary refractive surface of the eye.

About TYRVAYA^TM (varenicline solution) Nasal Spray
TYRVAYA (varenicline solution) Nasal Spray 0.03 mg (formerly referred to as OC-01 nasal spray) is a highly selective cholinergic agonist that is FDA-approved to treat the signs and symptoms of dry eye disease as a multidose nasal spray. The parasympathetic nervous system, the “rest and digest” system of the body, controls tear film homeostasis partially via the trigeminal nerve, which is accessible within the nose. The efficacy of TYRVAYA Nasal Spray in dry eye disease is believed to be the result of varenicline's activity at heteromeric sub-type(s) of the nicotinic acetylcholine (nACh) receptor where its binding produces agonist activity and activates the trigeminal parasympathetic pathway resulting in increased production of basal tear film as a treatment for dry eye disease. Varenicline binds with high affinity and selectivity at human α4β2, α4α6β2, α3β4, α3α5β4 and α7 neuronal nicotinic acetylcholine receptors. The exact mechanism of action is unknown at this time.

TYRVAYA^TM Important Safety Information
The most common adverse reaction reported in 82% of patients was sneezing. Events that were reported in 5-16% of patients were cough, throat irritation, and instillation-site (nose) irritation. There are no contraindications associated with TYRVAYA^TM (varenicline solution) Nasal Spray.

Please see full Prescribing Information at www.tyrvaya-pro.com/prescribinginformation.

About Oyster Point Pharma, Inc.
Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. In October 2021, Oyster Point Pharma received FDA approval for TYRVAYA^TM (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease. Oyster Point has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations. Oyster Point is continuously striving to advance breakthrough science and deliver therapies seeking to address the unmet needs of patients with ophthalmic disease and the eye care professionals who take care of them. For more information, visit www.oysterpointrx.com and follow @OysterPointRx on Twitter and LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current beliefs, expectations and assumptions of Oyster Point Pharma (the “Company” or “our”) regarding the future of the Company’s business, our future plans and strategies, regulatory approvals, preclinical and clinical results, future financial condition and other future conditions. All statements other than statements of historical facts contained in this press release, including express or implied statements regarding plans and objectives of management for future operations, future results of operations and financial position, business strategy, product candidates, regulatory approvals, planned future product commercialization, planned preclinical studies and clinical trials, expected results of preclinical studies or clinical trials, and their timing and likelihood of success, expected research and development commercialization costs, are forward-looking statements. The words “if approved,” “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our plans and potential for success relating to commercializing TYRVAYA; the beneficial characteristics, safety, efficacy and therapeutic effects of TYRVAYA and our preclinical and clinical product candidates; our plans relating to the further development and manufacturing of TYRVAYA and our preclinical and clinical candidates, including potential additional indications or disease areas to be evaluated and pursued; the timing of initiation of our future preclinical studies or clinical trials; the uncertainties inherent in pharmaceutical research and development, including preclinical study and clinical trial results and additional analysis of existing data; the likelihood of clinical trials demonstrating safety and efficacy of our product candidates, and other positive results; the timing or likelihood of regulatory filings and approvals TYRVAYA and our clinical and preclinical candidates, including in potential additional indications for TYRVAYA and potential filings in additional jurisdictions; our plans and ability to obtain or protect intellectual property rights including extensions of existing patent terms where available; our ability to recruit and retain key personnel needed to develop and commercialize our product candidates, if approved, and to grow our company; existing regulations and regulatory developments in the United States and other jurisdictions; our continued reliance on third parties to conduct additional preclinical studies and clinical trials of our product candidates, and for the manufacture of our product candidates for potential commercialization and for preclinical studies and clinical trials; the impact of the COVID-19 pandemic on our business, operations, and regulatory and clinical development timelines; the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our financial performance; market conditions; the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements; and other risks described in the “Risk Factors” section included in our public filings that we have made and will make with the Securities and Exchange Commission (SEC). The Company is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. 

Investor Contact
Tim McCarthy
LifeSci Advisors, LLC
(212) 915-2564
investors@oysterpointrx.com

Media Contact
Sheryl Seapy
Real Chemistry
(213) 262-9390
sseapy@realchemistry.com

Sources:

1. Market-Scope. 2020 Dry Eye Products Report: A Global Market Analysis for 2019 to 2025. October 2020.
2. Tsubota K, Pflugfelder S, Liu Z, Baudouin C. Defining dry eye from a clinical perspective. Int J Mol Sci. 2020;21(23):1-24.
   https://pubmed.ncbi.nlm.nih.gov/33291796/
3. Willcox, M. D., Argüeso, P., Georgiev, G. A., Holopainen, J. M., Laurie, G. W., Millar, T. J., ... & Jones, L. (2017). TFOS DEWS II tear film report. The ocular surface, 15(3), 366-403.
   
   

FAQ

What is the significance of Oyster Point Pharma's presentations at the AAO Annual Meeting 2021?

Oyster Point Pharma will showcase pivotal data on TYRVAYA^TM Nasal Spray, which addresses dry eye disease, an increasingly prevalent condition affecting millions in the U.S.

When and where are Oyster Point Pharma's presentations scheduled during the AAO Annual Meeting?

Oyster Point's presentations are scheduled for November 14, 2021, at the Morial Convention Center in New Orleans, LA.

What is TYRVAYA^TM and how does it help with dry eye disease?

TYRVAYA^TM (varenicline solution) is a nasal spray FDA-approved for treating the signs and symptoms of dry eye disease by enhancing tear film production.

How prevalent is dry eye disease in the U.S.?

Dry eye disease affects approximately 38 million people in the United States and is on the rise, creating a significant need for effective treatments.

What are the key findings from the ONSET-2 Phase 3 trial presented by Oyster Point Pharma?

The ONSET-2 Phase 3 trial presented by Oyster Point Pharma focuses on the efficacy and outcomes of OC-01 Nasal Spray in treating dry eye disease symptoms.